Sumanta K. Pal, MD, FASCO, on Tolerability of Lenvatinib and Everolimus to Treat Patients With RCC

Video

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® to detail a phase 2 trial (NCT03173560) of lenvatinib (Lenvima) at 2 starting doses and everolimus to treat patients with renal cell carcinoma, discussing challenges with tolerability of the drugs from a presentation at the 2021 Genitourinary Cancers Symposium.

Transcription:

This particular combination with lenvatinib and everolimus doesn’t include an [immunotherapy] component, it’s just pure targeted therapy. And I would suggest that, in terms of tolerability, it has its challenges. I was hoping that perhaps we could get away with using a lower dose and thereby mitigate some toxicity, but it doesn’t appear that that’s the case. It certainly does suggest to me that perhaps there are challenges as we try to implement the higher dose of lenvatinib with pembrolizumab. [In the CLEAR study (NCT02811861)], they use a dose of 20 mg of lenvatinib, but I can't imagine that that's going to be any easier for patients.

Reference:

Pal SK, Puente J, Heng DYK, et al. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). Presented at: 2021 Genitourinary Cancers Symposium. Abstract 307.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content